AAPL338.32-6.31 (-1.83%) ▼|ABBV288.84-6.05 (-2.05%) ▼|ABT110.16+3.96 (+3.73%) ▲|ACN260.94+2.70 (+1.05%) ▲|ADBE251.47+1.24 (+0.50%) ▲|AMAT374.53-15.56 (-3.99%) ▼|AMD466.84-37.96 (-7.52%) ▼|AMGN465.45-0.56 (-0.12%) ▼|AMT188.30+0.52 (+0.28%) ▲|AMZN245.63+5.28 (+2.20%) ▲|AVGO322.23-3.85 (-1.18%) ▼|AXP327.98+8.87 (+2.78%) ▲|BA175.40+3.85 (+2.24%) ▲|BAC49.57-0.44 (-0.88%) ▼|BKNG153.75+5.62 (+3.79%) ▲|BLK1,167.15+19.61 (+1.71%) ▲|BMY63.02+0.54 (+0.86%) ▲|BNY147.78+0.67 (+0.46%) ▲|BRK-B556.11+13.62 (+2.51%) ▲|C123.10+1.13 (+0.93%) ▲|CAT613.62-9.13 (-1.47%) ▼|CL97.43+2.14 (+2.25%) ▲|CMCSA23.87+0.65 (+2.80%) ▲|COF210.77+5.92 (+2.89%) ▲|COP146.84-7.19 (-4.67%) ▼|COST1,040.55+28.27 (+2.79%) ▲|CRM226.18-2.99 (-1.30%) ▼|CSCO101.61-2.90 (-2.77%) ▼|CVS88.51-1.74 (-1.93%) ▼|CVX227.77-7.75 (-3.29%) ▼|DE667.60-7.88 (-1.17%) ▼|DHR227.97-4.26 (-1.83%) ▼|DIS113.11+2.17 (+1.96%) ▲|DUK128.38+0.99 (+0.78%) ▲|EMR165.96+1.02 (+0.62%) ▲|FDX318.25+4.97 (+1.59%) ▲|GD373.46+0.87 (+0.23%) ▲|GE315.78+13.98 (+4.63%) ▲|GEV862.25+4.38 (+0.51%) ▲|GILD170.33-0.35 (-0.21%) ▼|GM89.94+2.54 (+2.91%) ▲|GOOG278.04-0.18 (-0.06%) ▼|GOOGL278.99-0.85 (-0.30%) ▼|GS898.72+4.17 (+0.47%) ▲|HD341.15+11.95 (+3.63%) ▲|HON223.77+5.44 (+2.49%) ▲|IBM252.51-5.30 (-2.06%) ▼|INTC59.97-5.79 (-8.80%) ▼|INTU352.10+11.01 (+3.23%) ▲|ISRG436.87+4.86 (+1.13%) ▲|JNJ270.56-2.64 (-0.97%) ▼|JPM340.58+3.54 (+1.05%) ▲|KO95.83+1.75 (+1.86%) ▲|LIN519.72+5.48 (+1.07%) ▲|LLY1,410.99-6.55 (-0.46%) ▼|LMT643.15+6.20 (+0.97%) ▲|LOW218.15+9.08 (+4.34%) ▲|LRCX227.56-11.55 (-4.83%) ▼|MA658.10+20.09 (+3.15%) ▲|MCD265.64+7.52 (+2.91%) ▲|MDLZ66.38+1.44 (+2.22%) ▲|MDT99.29+2.75 (+2.85%) ▲|META606.73-8.26 (-1.34%) ▼|MMM178.36+4.02 (+2.31%) ▲|MO77.17-0.86 (-1.10%) ▼|MRK148.36-1.16 (-0.78%) ▼|MS185.73+1.43 (+0.78%) ▲|MSFT507.12-14.79 (-2.83%) ▼|MU833.59-51.15 (-5.78%) ▼|NEE85.03+1.32 (+1.58%) ▲|NFLX62.34+0.26 (+0.42%) ▲|NKE39.12+0.45 (+1.16%) ▲|NOW106.01+0.89 (+0.85%) ▲|NVDA202.06-2.58 (-1.26%) ▼|ORCL119.22-11.45 (-8.76%) ▼|PEP140.42+3.08 (+2.24%) ▲|PFE30.67+0.15 (+0.49%) ▲|PG163.56+1.99 (+1.23%) ▲|PLTR178.34-5.77 (-3.13%) ▼|PM208.29-0.50 (-0.24%) ▼|QCOM162.08-2.71 (-1.64%) ▼|RTX202.79+2.99 (+1.50%) ▲|SBUX104.40+0.75 (+0.72%) ▲|SCHW88.71+0.66 (+0.75%) ▲|SO94.61+0.90 (+0.96%) ▲|SPG221.73+3.98 (+1.83%) ▲|T21.44+0.03 (+0.14%) ▲|TMO682.65-14.35 (-2.06%) ▼|TMUS160.15+3.71 (+2.37%) ▲|TSLA403.82+4.01 (+1.00%) ▲|TXN302.02+1.18 (+0.39%) ▲|UBER66.71+1.46 (+2.24%) ▲|UNH400.44-6.53 (-1.60%) ▼|UNP307.00+3.00 (+0.99%) ▲|UPS109.71+1.46 (+1.35%) ▲|USB60.49+1.04 (+1.75%) ▲|V425.51+11.92 (+2.88%) ▲|VZ45.05+0.32 (+0.72%) ▲|WFC85.89+2.49 (+2.99%) ▲|WMT127.69+4.18 (+3.38%) ▲|XOM179.67-7.58 (-4.05%) ▼|AAPL338.32-6.31 (-1.83%) ▼|ABBV288.84-6.05 (-2.05%) ▼|ABT110.16+3.96 (+3.73%) ▲|ACN260.94+2.70 (+1.05%) ▲|ADBE251.47+1.24 (+0.50%) ▲|AMAT374.53-15.56 (-3.99%) ▼|AMD466.84-37.96 (-7.52%) ▼|AMGN465.45-0.56 (-0.12%) ▼|AMT188.30+0.52 (+0.28%) ▲|AMZN245.63+5.28 (+2.20%) ▲|AVGO322.23-3.85 (-1.18%) ▼|AXP327.98+8.87 (+2.78%) ▲|BA175.40+3.85 (+2.24%) ▲|BAC49.57-0.44 (-0.88%) ▼|BKNG153.75+5.62 (+3.79%) ▲|BLK1,167.15+19.61 (+1.71%) ▲|BMY63.02+0.54 (+0.86%) ▲|BNY147.78+0.67 (+0.46%) ▲|BRK-B556.11+13.62 (+2.51%) ▲|C123.10+1.13 (+0.93%) ▲|CAT613.62-9.13 (-1.47%) ▼|CL97.43+2.14 (+2.25%) ▲|CMCSA23.87+0.65 (+2.80%) ▲|COF210.77+5.92 (+2.89%) ▲|COP146.84-7.19 (-4.67%) ▼|COST1,040.55+28.27 (+2.79%) ▲|CRM226.18-2.99 (-1.30%) ▼|CSCO101.61-2.90 (-2.77%) ▼|CVS88.51-1.74 (-1.93%) ▼|CVX227.77-7.75 (-3.29%) ▼|DE667.60-7.88 (-1.17%) ▼|DHR227.97-4.26 (-1.83%) ▼|DIS113.11+2.17 (+1.96%) ▲|DUK128.38+0.99 (+0.78%) ▲|EMR165.96+1.02 (+0.62%) ▲|FDX318.25+4.97 (+1.59%) ▲|GD373.46+0.87 (+0.23%) ▲|GE315.78+13.98 (+4.63%) ▲|GEV862.25+4.38 (+0.51%) ▲|GILD170.33-0.35 (-0.21%) ▼|GM89.94+2.54 (+2.91%) ▲|GOOG278.04-0.18 (-0.06%) ▼|GOOGL278.99-0.85 (-0.30%) ▼|GS898.72+4.17 (+0.47%) ▲|HD341.15+11.95 (+3.63%) ▲|HON223.77+5.44 (+2.49%) ▲|IBM252.51-5.30 (-2.06%) ▼|INTC59.97-5.79 (-8.80%) ▼|INTU352.10+11.01 (+3.23%) ▲|ISRG436.87+4.86 (+1.13%) ▲|JNJ270.56-2.64 (-0.97%) ▼|JPM340.58+3.54 (+1.05%) ▲|KO95.83+1.75 (+1.86%) ▲|LIN519.72+5.48 (+1.07%) ▲|LLY1,410.99-6.55 (-0.46%) ▼|LMT643.15+6.20 (+0.97%) ▲|LOW218.15+9.08 (+4.34%) ▲|LRCX227.56-11.55 (-4.83%) ▼|MA658.10+20.09 (+3.15%) ▲|MCD265.64+7.52 (+2.91%) ▲|MDLZ66.38+1.44 (+2.22%) ▲|MDT99.29+2.75 (+2.85%) ▲|META606.73-8.26 (-1.34%) ▼|MMM178.36+4.02 (+2.31%) ▲|MO77.17-0.86 (-1.10%) ▼|MRK148.36-1.16 (-0.78%) ▼|MS185.73+1.43 (+0.78%) ▲|MSFT507.12-14.79 (-2.83%) ▼|MU833.59-51.15 (-5.78%) ▼|NEE85.03+1.32 (+1.58%) ▲|NFLX62.34+0.26 (+0.42%) ▲|NKE39.12+0.45 (+1.16%) ▲|NOW106.01+0.89 (+0.85%) ▲|NVDA202.06-2.58 (-1.26%) ▼|ORCL119.22-11.45 (-8.76%) ▼|PEP140.42+3.08 (+2.24%) ▲|PFE30.67+0.15 (+0.49%) ▲|PG163.56+1.99 (+1.23%) ▲|PLTR178.34-5.77 (-3.13%) ▼|PM208.29-0.50 (-0.24%) ▼|QCOM162.08-2.71 (-1.64%) ▼|RTX202.79+2.99 (+1.50%) ▲|SBUX104.40+0.75 (+0.72%) ▲|SCHW88.71+0.66 (+0.75%) ▲|SO94.61+0.90 (+0.96%) ▲|SPG221.73+3.98 (+1.83%) ▲|T21.44+0.03 (+0.14%) ▲|TMO682.65-14.35 (-2.06%) ▼|TMUS160.15+3.71 (+2.37%) ▲|TSLA403.82+4.01 (+1.00%) ▲|TXN302.02+1.18 (+0.39%) ▲|UBER66.71+1.46 (+2.24%) ▲|UNH400.44-6.53 (-1.60%) ▼|UNP307.00+3.00 (+0.99%) ▲|UPS109.71+1.46 (+1.35%) ▲|USB60.49+1.04 (+1.75%) ▲|V425.51+11.92 (+2.88%) ▲|VZ45.05+0.32 (+0.72%) ▲|WFC85.89+2.49 (+2.99%) ▲|WMT127.69+4.18 (+3.38%) ▲|XOM179.67-7.58 (-4.05%) ▼|
12.2 C
New York
Tuesday, November 3, 2026

Tag: partners

newsFORsourcecompanycontentinformationreleases1market

Zymeworks Presents New Phase 1 Data for Folate Receptor Alpha-Targeting ADC ZW191 at ESMO Gynaecological Cancers Congress 2026

VANCOUVER, British Columbia, June 14, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets while developing a diverse pipeline of novel, multifunctional biotherapeutics, today presented new clinical data from the dose-escalation portion of its ongoing Phase 1 study evaluating ZW191, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), at the European Society for Medical Oncology (ESMO) Gynaecological Cancers Congress 2026.

Prime Minister Carney expands Canada’s partnership with Ireland across science, technology, and culture

WESTPORT, Ireland, June 14, 2026 /CNW/ - In a more dangerous and divided world, Canada is building our strength at home and diversifying our...

SAMARITAN’S PURSE EBOLA TREATMENT CENTERS OPEN IN THE EPICENTER OF THE DEADLY OUTBREAK

BOONE, N.C., June 14, 2026 /PRNewswire/ -- Samaritan's Purse has established two Ebola Treatment Centers in Bunia and Nyankunde, Democratic Republic of Congo (DRC), to...

Ddrops® Championed Active Childhoods and Healthy Growth at Aqua Champs League Fest 2026 Malaysia

KUALA LUMPUR, Malaysia, June 14, 2026 /PRNewswire/ -- Ddrops®, a Canadian family health and nutritional supplement brand, participated as a supporting sponsor of Aqua...

Changan Group Unveils Its In-house Developed ADAS — SDA Pilot

CHONGQING, China, June 14, 2026 /PRNewswire/ -- At the 28th Chongqing International Auto Exhibition, Changan Group showcased its full brand lineup including CHANGAN NEVO,...

Legend Biotech Establishes Clinical Proof-of-Concept for LB2501, a Potential First-in-Class In Vivo CD19/CD20 Dual-Targeting CAR-T, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma

BRIDGEWATER, N.J., June 14, 2026 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, today announced first clinical proof-of-concept data for LB2501, its investigational in vivo CD19/CD20 dual-targeting CAR-T cell therapy, in patients with relapsed or refractory B-cell non-Hodgkin lymphoma (R/R B-NHL). The results are being presented today in a late-breaking session at the European Hematology Association (EHA) 2026 Congress (Abstract #LB5006).

TAIWAN DESIGN POWER Debuts at Busan Design Festival, Showcasing Taiwan’s Design Innovation and Creative Value

The "TAIWAN DESIGN POWER" Taiwan Pavilion, showcased at the Busan Design Festival in South Korea, brings together 25 design projects and 20 industry representatives, demonstrating...

Marler Clark Urges Parents to Stop Using Nara Organics Whole Milk Organic Powdered Infant Formula Amid Multistate Infant Botulism Outbreak — Product Sold Nationwide...

FDA, CDC, and public health officials in California, Pennsylvania, and Washington are investigating; food safety attorney Bill Marler calls it the second formula-linked infant...

Air Canada and the IAMAW Reach Tentative Agreement on New Contract

MONTRÉAL, June 13, 2026 (GLOBE NEWSWIRE) -- Air Canada today said it has reached a tentative collective agreement with the International Association of Machinists and Aerospace Workers (IAMAW) representing more than 11,000 Air Canada employees in Maintenance, Cabin Services, Airport Airside Operations, Cargo, Finance and Clerical.

“New US Social Casino Bonus: 200% Match + 10 SC Coins” – by Acebet

Acebet social casino now credits 10 free Sweeps Coins at signup, no purchase required, and matches a player's first Gold Coin package at 200%: making this the best social casino signup bonus as of June 2026. 
Acebet social casino now credits 10 free Sweeps Coins at signup, no purchase required, and matches a player's first Gold Coin package at 200%: making this the best social casino signup bonus as of June 2026.

HeroMD 4-MAX Claims Evaluated: Why Men Searching “Most Effective 4-in-1 Erectile Dysfunction Formula” Are Comparing SURGE, PRIME and The HERO System Explained

HeroMD 4-MAX scam or legit? Compounded 4-in-1 sublingual ED formula with 10-min onset and 36-hr window reviewed.

Kos Biotechnology Partners Announces Third Closing of Global Life Sciences Fund at $123 Million

NEW YORK and ATHENS, Greece, June 13, 2026 /PRNewswire/ -- Kos Biotechnology Partners ("Kos"), a global life sciences investment firm bridging the US biopharma...

Kos Biotechnology Partners Announces Third Closing of Global Life Sciences Fund at $123 Million

NEW YORK and ATHENS, Greece, June 13, 2026 /PRNewswire/ -- Kos Biotechnology Partners ("Kos"), a global life sciences investment firm bridging the US biopharma...

MGI Tech Showcases Expanding Genomics Ecosystem at ESHG 2026 with New IVD Partnering Program and OEM Collaborations

GOTHENBURG, Sweden, June 13, 2026 /PRNewswire/ -- MGI Tech Co., Ltd. (MGI), a company committed to developing core tools and technologies that drive innovation...

- A word from our sponsors -

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsPartners

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers